Practice guidelines for outpatient parenteral antimicrobial therapy

Clinical Infectious Diseases

Volumn 38, Issue 12, 2004, Pages 1651-1672

  Tice, Alan D ^a   Rehm, Susan J ^b   Dalovisio, Joseph R ^c   Bradley, John S ^d   Martinelli, Lawrence P ^e   Graham, Donald R ^f   Gainer, R Brooks ^g   Kunkel, Mark J ^h   Yancey, Robert W ⁱ   Williams, David N ^j  

^a UNIVERSITY OF HAWAII   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c OCHSNER CLINIC FOUNDATION   (United States)

^d RADY CHILDREN'S HOSPITAL   (United States)

^e Department of Infectious Diseases ^*  (United States)

^f Springfieid Clinic   (United States)

^g Morgantown Internal Medicine Group   (United States)

^h PFIZER INC   (United States)

ⁱ Florida Infection Physicians   (United States)

^j HENNEPIN COUNTY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; AMPICILLIN; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BETA LACTAM ANTIBIOTIC; CASPOFUNGIN; CEFAZOLIN; CEFEPIME; CEFOPERAZONE; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CHLORAMPHENICOL; CLINDAMYCIN; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN LACTOBIONATE; GANCICLOVIR; MEROPENEM; NAFCILLIN; OXACILLIN; PENICILLIN G; SULTAMICILLIN; UNINDEXED DRUG; VANCOMYCIN;

ANAPHYLAXIS; ANEMIA; ANTIMICROBIAL THERAPY; BACTEREMIA; BACTERIAL ARTHRITIS; CAREGIVER; CELLULITIS; CLINICAL EXAMINATION; DEVICE INFECTION; DIARRHEA; DRUG EFFECT; DRUG HALF LIFE; DRUG STABILITY; DRUG STORAGE; FEVER; HEALTH PROGRAM; HOME CARE; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; LYME DISEASE; MEDICAL DECISION MAKING; MENINGITIS; NAUSEA; NURSE; OSTEOMYELITIS; OUTPATIENT; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SELECTION; PHARMACIST; PHLEBITIS; PHYSICIAN; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PYELONEPHRITIS; RASH; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; URTICARIA; VESTIBULAR DISORDER; WOUND INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; CHILD; DRUG MONITORING; HOME CARE SERVICES; HOME INFUSION THERAPY; HUMANS; INFUSIONS, INTRAVENOUS; OUTCOME ASSESSMENT (HEALTH CARE); OUTPATIENTS; PATIENT CARE TEAM; PATIENT SELECTION; PEDIATRICS;

EID: 2942678701     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/420939     Document Type: Review

References (237)

1. Antoniskis A, Anderson BC, Van Volkinburg EJ, Jackson JM, Gilbert DN. Feasibility of outpatient self-administration of parenteral antibiotics. West J Med 1978; 128:203-6.
2. Grayson ML, Silvers J, Turnidge J. Home intravenous antibiotic therapy: a safe and effective alternative to inpatient care. Med J Aust 1995; 162:249-53.
3. Kayley J, Berendt AR, Snelling MJM, et al. Antimicrobial practice. Safe intravenous antibiotic therapy at home: experience of a UK based program. J Antimicrob Chemother 1996; 37:1023-9.
4. Kind AC, Williams DN, Persons G, Gibson JA. Intravenous antibiotic therapy at home. Arch Intern Med 1979; 139:413-5.
5. Poretz DM, Eron LJ, Goldenberg RI, et al. Intravenous antibiotic therapy in an outpatient setting. JAMA 1982; 248:336-9.
6. Rehm SJ, Weinstein AJ. Home intravenous antibiotic therapy: a team approach. Ann Intern Med 1983; 99:388-92.
7. Rucker RW, Harrison GM. Outpatient intravenous medications in the management of cystic fibrosis. Pediatrics 1974; 54:358-60.
8. Tice AD. An office model of outpatient parenteral antibiotic therapy. Rev Infect Dis 1991; 13(Suppl 2):S184-8.
9. Winter RJD, George R, Deacock S, et al. Self-administered home intravenous antibiotic therapy in bronchiectasis and adult cystic fibrosis. Lancet 1984; 1:1338-9.
10. Winters RW, Parver AK, Sansbury JD. Home infusion therapy: a service and demographic profile: a report for the National Alliance for Infusion Therapy. Washington, DC: National Alliance for Infusion Therapy, 1992:1-61.
11. Williams DN, Rehm SJ, Tice AD, Bradley JS, Kind AC, Craig WA. Practice guidelines for community-based parenteral anti-infective therapy. Clin Infect Dis 1997; 25:787-801.
12. Tice AD. Outpatient parenteral antibiotic therapy: management of serious infections. I. Medical, socioeconomic, and legal issues: the team concept. Hosp Pract (Off Ed) 1993; 28(Suppl 1):6-10.
13. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31:347-82.
14. Auble TE, Yealy DM, Fine MJ. Assessing prognosis and selecting an initial site of care for adults with community-acquired pneumonia. Infect Dis Clin North Am 1998; 12:741-59.
15. McCormick D, Fine MJ, Coley CM, et al. Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes? Am J Med 1999; 107:5-12.
16. Niederman MS, Bass JB, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148:1418-26.
17. Fine MJ, Hough LJ, Medsger AR, et al. The hospital admission decision for patients with community-acquired pneumonia. Arch Intern Med 1997; 157:36-44.
18. Fine MJ, Medsger AR, Stone RA, et al. The hospital discharge decision for patients with community-acquired pneumonia. Arch Intern Med 1997; 157:47-56.
19. Rehm SJ. Outpatient intravenous antibiotic therapy for endocarditis. Infect Dis Clin North Am 1998; 12:879-901.
20. Francioli P, Etienne J, Hoigne R, Thys JP, Gerber A. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks: efficacy and outpatient treatment feasibility. JAMA 1992; 267:264-7.
21. Stamboulian D, Bonvehi P, Arevalo C, et al. Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci. Rev Infect Dis 1991; 13:5160-3.
22. Sexton DJ, Tenenbaum MJ, Wilson WR, et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to pencillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clin Infect Dis 1998; 27:1470-4.
23. Andrews MM, von Reyn CE Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis. Clin Infect Dis 2001; 33:203-9.
24. Brown RB. Selection and training of patients for outpatient intravenous antibiotic therapy. Rev Infect Dis 1991; 13:5147-51.
25. Poretz DM. Home management of antibiotic therapy. Curr Clin Top Infect Dis 1989; 10:27-42.
26. Infusion Nurses Society. Infusion nursing standards of practice. J Intraven Nurs 2002; 23(Suppl 6):S1-88.
27. Chung M, Akahoshi M. Reducing home nursing visit costs using a remote access infusion pump system. J Intraven Nurs 1999; 22:309-14.
28. DeMaio J, Schwartz L, Cooley P, Tice AD. The application of telemedicine technology to a directly observed therapy program for tuberculosis: a pilot project. Clin Infect Dis 2001; 33:2082-4.
29. Nolet BR. Patient selection in outpatient parenteral antimicrobial therapy. Infect Dis Clin North Am 1998; 12:835-47.
30. Miller Z. Health maintenance organization. Hosp Pract 1993; 28(Suppl 2):44-47.
31. Hankwitz PE, Keenan JM. The expanding and increasingly important role of the home health care agency medical director. Am Ac Home Care Phys Newsletter 1994; 6:8-10.
32. Goldberg AI, Gardner HG, Gibson LE. Home care: the next frontier of pediatric practice. J Pediatr 1994; 125:686-90.
33. Tice AD. Growing pains in outpatient intravenous antibiotic therapy. Infect Dis Clin Pract 1993; 1:74-6.
34. American Society of Hospital Pharmacists (ASHP). ASHP statement on the pharmacist's role with respect to drug delivery systems and administration devices. Am J Hosp Pharm 1993; 1724-5.
35. American Society of Health-System Pharmacists (ASHP). ASHP guidelines on the pharmacist's role in home care. Am J Health Syst Pharm 2000; 57:1252-7.
36. Wickline v State of California, 228 Cal. Rptr. 661, 192. Cap. App. 3d 1630, 1986.
37. Physicians, surgeons and other healers. American Jurisprudence, 2d ed. Rochester, NY: Lawyers' Cooperative Publishing Company, 1981; 226.
38. Tice AD, Nolet BR. Delivery models for outpatient parenteral antimicrobial therapy. In: Outpatient parenteral antimicrobial therapy: current status. Scientific American Medicine special report 1997:7-11.
39. Bakken JS, Conlon CP, Smerud KT, Vinen JD, Wijlhuizen TG. Antibiotic administration options. Infect Dis Clin Pract 1996; 5:66-7.
40. Nathwani D, Seaton A, Davey P. Key issues in the development of a non-inpatient intravenous (NIPIV) antibiotic therapy programme - a European perspective. Rev Med Microbiol 1997; 8:137-47.
41. Nathwani D, Conlon CP. Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party. Clin Microbiol Infect 1998; 4:537-51.
42. Tice AD. The importance of teamwork for outpatient parenteral antibiotic therapy. Int J Antimicrob Agents 1995; 5:13-7.
43. Williams DN, Raymond JL. Practice guidelines for community-based parenteral anti-infective therapy. Infect Dis Clin North Am 1998; 12: 1009-21.
44. Residency Review Committee. Specific program content. CAAR Program Information from Workshop for Internal Medicine Subspecialty Residencies in Infectious Disease. 11. 2001. American Board of Internal Medicine. Ref Type: Conference Proceeding.
45. Lonsway RAW. Intravenous therapy in the home. In: Hankins J, Lonsway RAW, Hedrick C, Perdue MD, eds. Infusion therapy in clinical practice. 2d ed. Philadelphia: W.B. Saunders, 2001:501-34.
46. Mortlock N. Intravenous therapy in the alternative care setting. In: Como D, Myers T, eds. Infusion therapy in clinical practice. Philadelphia: W.B. Saunders, 2001:535-60.
47. Williams DN, Raymond JL. Community-based parenteral anti-infective therapy (CoPAT): pharmacokinetic and monitoring issues. Clinical Pharmacokinetics 1998; 35:65-77.
48. US Public Health Service. Updated US Public Health Service Guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep 2001; 50(RR-11):1-52.
49. Tice AD. Bloodborne pathogen exposure and recommendations for management. J Infus Nurs 2002; 25(Suppl 6):S5-9.
50. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080-4.
51. Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Arch Intern Med 2002; 162:682-8.
52. Norgard B, Sorensen HT, Jensen ES, Faber T, Schonheyder HC, Nielsen GL. Pre-hospital parenteral antibiotic treatment of meningococcal disease and case fatality: a Danish population-based cohort study. J Infect 2002; 45:144-51.
53. Chemaly RF, de Parres JB, Rehm SJ, et al. Venous thrombosis associated with peripherally inserted central catheters: a retrospective analysis of the Cleveland Clinic experience. Clin Infect Dis 2002; 34: 1179-83.
54. Garrelts JC, Ast D, LaRocca J, Smith DF, Peterie JD. Postinfusion phlebitis after intravenous push versus intravenous piggyback administration of antimicrobial agents. Clin Pharm 1988; 7:760-5.
55. Nowobilski-Vasilios A, Poole SM. Development and preliminary outcomes of a program for administering antimicrobials by i.v. push in home care. Am J Health Syst Pharm 1999; 56:76-9.
56. Skokal W. IV push at home? RN 2000; 63:26-9.
57. Dew RI, Sulsa G. Once-daily aminoglycoside treatment. Infect Dis Clin Pract 1996; 5:12-24.
58. McNulty TJ. Home care exchange: initiation of antimicrobial therapy in the home. Am J Hosp Pharm 1993; 50:773-4.
59. Tulkens PM. Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Chemother 1991; 27(Suppl C):49-61.
60. Craig WA. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. Eur J Clin Microbiol Infect Dis 1995; 14:636-42.
61. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 1992; 36:2577.
62. Cutler NR, Narang PK, Lesko LJ, Ninos M, Power M. Vancomycin disposition: the importance of age. Clin Pharmacol Ther 1984; 36: 803-10.
63. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control 1995; 23:87-94.
64. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565-7.
65. Barton AJ, Danek G, Johns P, Coons M. Improving patient outcomes through CQI: vascular access planning. J Nurs Care Qual 1998; 13: 77-85.
66. Graham DR, Keldermans MM, Klemm LW, Semenza NJ, Shafer ML. Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous catheters. Am J Med 1991; 91:95S-100S.
67. Ng PK, Ault MD, Ellrodt AG, Maldonado L. Peripherally inserted central catheters in general medicine. Mayo Clin Proc 1997; 72: 225-33.
68. Thiagarajan RR, Ramamoorthy C, Gettmann T, Bratton SL. Survey of the use of peripherally inserted central venous catheters in children. Pediatrics 1997; 99:E4.
69. National Association of Vascular Access Networks. Tip location of peripherally inserted central catheters. J Vascular Access Devices 1998; 3:8-10.
70. Racadio JM, Doellman DA, Johnson ND, Bean JA, Jacobs BR. Pediatric peripherally inserted central catheters: complication rates related to catheter tip location. Pediatrics 2001; 107:E28.
71. Allen AW, Megargell JL, Brown DB, et al. Venous thrombosis associated with the placement of peripherally inserted central catheters. J Vasc Interv Radiol 2000; 11:1309-14.
72. James L, Bledsoe L, Hadaway LC. A retrospective look at tip location and complications of peripherally inserted central catheter lines. J Intraven Nurs 1993; 16:104-9.
73. Tice AD, Seibold G, Martinelli LP. Adverse effects with intravenous antibiotics with OPAT. In: Program and abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America (IDSA) (Chicago) [abstract 59]. Alexandria, VA: IDSA, 2002.
74. Hoffman-Terry ML, Fraimow HS, Fox TR, Swift BG, Wolf JE. Adverse effects of outpatient parenteral antibiotic therapy. Am J Med 1999; 106:44-9.
75. Berman SJ, Johnson EW. Out-patient parenteral antibiotic therapy (OPAT): clinical outcomes and adverse events. Hawaii Med J 2001; 60:31-3.
76. Cunha BA. Antibiotic side effects. Med Clin North Am 2001; 85: 149-85.
77. Rehm SJ, Longworth DL. Rates of adverse events associated with community-based parenteral anti-infective therapy. J Clin Outcomes Manage 2000; 7:23-8.
78. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39:650-5.
79. Urban AW, Craig WA. Daily dosage of aminoglycosides. Curr Clin Top Infect Dis 1997; 17:236-55.
80. Contreras AM, Gamba G, Cortes J, et al. Serial trough and peak amikacin levels in plasma as predictors of nephrotoxicity. Antimicrob Agents Chemother 1989; 33:973-6.
81. Bertino JSJ, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167:173-9.
82. Moore RD, Smith CR, Lietman PS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 1984; 149:23-30.
83. Paterson DL, Robson JM, Wagener MM. Risk factors for toxicity in elderly patients given aminoglycoside once daily. J Gen Intern Med 1998; 13:735-9.
84. Minor LB. Gentamicin-induced bilateral vestibular hypofunction. JAMA 1998; 279:541-4.
85. Demer JL, Honrubia V, Baloh RW. Dynamic visual acuity: a test for oscillopsia and vestibulo-ocular reflex function. Am J Otol 1994; 15: 340-7.
86. Longridge NS, Mallinson AI. The dynamic illegible E-test: a technique for assessing the vestibulo-ocular reflex. Acta Otolaryngol 1987; 103: 273-9.
87. Brummett RE, Morrison RB. The incidence of aminoglycoside antibiotic-induced hearing loss. Arch Otolaryngol Head Neck Surg 1990; 116:406-10.
88. Martinelli L. Aminoglycoside questionnaire results. OPIVITA Newsletter, 1988.
89. Davey PG, Jabeen FJ, Harpur ES, Shenoi PM, Geddes AM. A controlled study of the reliability of pure tone audiometry for the detection of gentamicin auditory toxicity. J Laryngol Otol 1983; 97: 27-36.
90. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 18:533-43.
91. Tobin CM, Darville JM, Thomson AH, et al. Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. J Antimicrob Chemother 2002; 50: 713-8.
92. Fernandez de Gatta MD, Calvo MV, Hernandez JM, Caballero D, San Miguel JF, Dominguez-Gil A. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther 1996; 60:332-40.
93. Rybak MJ, Boike SC. Monitoring vancomycin therapy. Drug Intell Clin Pharm 1986; 20:757-61.
94. Gendeh BS, Gibb AG, Aziz NS, Kong N, Zahir ZM. Vancomycin administration in continuous ambulatory peritoneal dialysis: the risk of ototoxicity. Otolaryngol Head Neck Surg 1998; 118:551-8.
95. de Hoog M, van Zanten BA, Hop WC, Overbosch E, Weisglas-Kuperus N, van den Anker JN. Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss. J Pediatr 2003; 142:41-6.
96. Bhatt-Mehta V, Schumacher RE, Faix RG, Leady M, Brenner T. Lack of vancomycin-associated nephrotoxicity in newborn infants: a case-control study. Pediatrics 1999; 103:E48.
97. Sorrell TC, Collignon PJ. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 1985; 16:235-41.
98. Karam CM, McKinnon PS, Neuhauser MM, Rybak MJ. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy 1999; 19:257-66.
99. Kralovicova K, Spanik S, Halko J, Netriova J, Studena-Mrazova M, Novotny J. Do serum vancomycin levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients? J Chemother 1997; 9:420-6.
100. Knudsen JD, Fuursted K, Raber S, Espersen F, Frimodt-Moller N. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob Agents Chemother 2000; 44:1247-54.
101. Zokufa HZ, Rodvold KA, Blum RA, et al. Simulation of vancomycin peak and trough concentrations using five dosing methods in 37 patients. Pharmacotherapy 1989; 9:10-16.
102. Rodman DP, McKnight JT, Rogers T, Robbins M. The appropriateness of initial vancomycin dosing. J Fam Pract 1994; 38:473-7.
103. Pryka RD, Rodvold KA, Garrison M, Rotschafer JC. Individualizing vancomycin dosing regimens: one- versus two-comparment Bayesian models. Ther Drug Monit 1998; 11:450-4.
104. Pea F, Prooeca L, Baraldo M, Furlanut M. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000; 45:329-35.
105. Penzak SR, Gubbins PO, Rodvold KA, Hickerson SL. Therapeutic drug monitoring of vancomycin in a morbidly obese patient. Ther Drug Monit 1998; 20:261-5.
106. Gous AG, Dance MD, Lipman J, Luyt DK, Mathivha R, Scribante J. Changes in vancomycin pharmacokinetics in critically ill infants. Anaesth Intensive Care 1995; 23:678-82.
107. Reed RL II, Wu AH, Miller-Crotchett P, Crotchett J, Fischer RP. Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients. Trauma 1989; 29:1462-8.
108. Rodvold KA, Everett JA, Pryka RD, Kraus DM. Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children. Clin Pharmacokinet 1997; 33:32-51.
109. Taber DJ, Fann AL, Malat G, Dupuis RE. Evaluation of estimated and measured ceratinine clearances for predicting ther pharmacokinetics of vancomycin in adult liver transplant recipients. Ther Drug Monit 2003; 25:67-72.
110. Bearden DT, Rodvold KA. Dosage adjustments for antibacterials in obese patients: applying pharamacokinetics. Clin Pharmacokinet 2000; 38:5-26.
111. Miles MV, Li L, Lakkis H, Youngblood J, McGinnis P. Special considerations for monitoring vancomycin concentrations in pediatric patients. Ther Drug Monit 1997; 19:265-70.
112. Le Normand Y, Milpied N, Kergueris MF, Harousseau JL. Pharmacokinetic parameters of vancomycin for therapeutic regimens in neutropenic adult patients. Int J Biomed Comput 1994; 36:121-5.
113. Guay DR, Vance-Bryan K, Gilliland S, Roddvoid K, Rotschafer JC. Comparision of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J Clin Pharmacol 1993; 33:918-22.
114. Asbury WH, Darsey EH, Rose WB, Murphy JE, Buffington DE, Capers CC. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. Ann Pharmacother 1993; 27:490-6.
115. Garrelts JC, Peterie JD. Altered vancomycin dose vs. serum concentration relationship in burn patients. Clin Pharmacol Ther 1988; 44: 9-13.
116. Pou L, Rosell M, Lopez R, Pascual C. Changes in vancomycin pharmacokinetics during treatment. Ther Drug Monit 1996; 18:149-53.
117. Schentag JJ. Antimicrobial action and phamacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J Chemother 1999; 11:426-39.
118. Hautekeete ML. Hepatotoxicity of antibitoics. Acta Gastroenterol Belg 1995; 58:290-6.
119. Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy 2001; 21:1010-3.
120. Peralta FG, Sanchez MB, Roiz MP, Pena MA, Tejero MA, Arjona R. Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam. Clin Infect Dis 2003; 37:1568-72.
121. Cobos E, Dixon S, Keung YK. Prevention and management of central venous catheter thrombosis. Curr Opin Hematol 1998; 5:355-9.
122. Centers for Disease Control and Prevention. Guidelines for the prevention of intravascular catheter-related infections. MMWR Morb Mortal Wkly Rep 2002; 51(RR-10):1-29.
123. Mermel LA, Farr BM, Sherertz R, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32: 1249-72.
124. Lee AY, Ginsberg JS. Venous thrombosis of the upper extremities. Current Treatment Options in Cardiovascular Medicine 2001; 3: 207-14.
125. Bregenzer T, Conen D, Sakmann P, Widmer AF. Is routine replacement of peripheral intravenous catheters necessary? Arch Intern Med 1998; 158:151-6.
126. Tice AD. Pharmacoeconomic considerations in the ambulatory use of parenteral cephalosporins. Drugs 2000; 59:29-35.
127. Popovich ML. Sentinel events in home care and hospice organizations. Home Care Provid 2000; 5:78-80.
128. 2000-2001 Comprehensive accreditation manual for ambulatory care. Oakbrook Terrace, IL: Joint Commission on Accreditation for Healthcare Organizations, 1999.
129. Barrell JM. ORYX: outcomes measurement and accreditation. Infusion 1998; May:37-9.
130. Bradley JS, Behrendt CE, Arrieta AC, et al. Convalescent phase outpatient parenteral antiinfective therapy for children with complicated appendicitis. Pediatr Infect Dis J 2001; 20:19-24.
131. Guglielmo BJ, Luber AD, Paletta D, Jacobs RA. Ceftriaxone therapy for staphylococcal osteomyelitis: a review. Clin Infect Dis 2000; 30: 205-7.
132. Kunkel MJ. Quality assurance and outcomes in outpatient parenteral antibiotic therapy. Infect Dis Clin North Am 1998; 12:1023-34.
133. Poole SM, Vasilios AN. Outcomes measurements: making sense of the data. Infusion 1998; May:25-8.
134. Tice AD. Patient selection criteria for outpatient parenteral antibiotic therapy: experience with a physician-directed, clinic-based program for outpatient parenteral antibiotic therapy in the USA. Eur J Clin Microbiol Infect Dis 1995; 14:655-61.
135. Tice AD. Documenting the value of OPAT: outcomes studies and patient registries. Can J Infect Dis 2000; 10:45A-8A.
136. Tice AD, Schleis TG, Nolet BR, Hoaglund PA, Kunkel MJ, Page US. Outcomes registry for outpatient IV antimicrobial therapy. Infusion 2000; May:27-35.
137. Tice AD. The use of outpatient parenteral antimicrobial therapy in the management of osteomyelitis: data from the outpatient parenteral antimicrobial therapy outcomes registry. Chemotherapy 2001; 47: 5-16.
138. Williams DN. Home intravenous antibiotic therapy (HIVAT): indications, patients and antimicrobial agents. Int J Antimicrob Agents 1995; 5:3-8.
139. Tice AD, Hoaglund PA, Shoultz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 2003; 114:723-8.
140. Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother 2003; 51:1261-8.
141. Donati MA, Guenette G, Auerbach H. Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease. J Pediatr 1987; 111:28-33.
142. Hjelte L, Widen B, Malmborg AS, Freyschuss U, Strandvik B. Intravenous administration of antibiotics at home in patients with cystic fibrosis improves quality of life. Lakartidningen 1988; 85:1614-7.
143. Kuzemko JA. Home treatment of pulmonary infection in cystic fibrosis. Chest 1988; 94:1625-1665.
144. Strandvik B, Hjelte L, Malmborg AS, Widen B. Home intravenous antibiotic treatment of patients with cystic fibrosis. Acta Paediatr 1992; 81:340-4.
145. Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J 1997; 10:896-900.
146. Caplan GA, Ward JA, Brennan NJ, Coconis J, Board N, Brown A. Hospital in the home: a randomised controlled trial. MJA 1999; 170: 156-60.
147. Nathwani D, Tice AD. Ambulatory antimicrobial use: the value of an outcomes registry. J Antimicrob Chemother 2002; 49:149-54.
148. Outpatient Parenteral Antimicrobial Therpay Outcomes Registry Web site. Available at: http://www.opat.com. Accessed 22 April 2004.
149. Tice AD, Seibold G, Martinelli LP. Reasons for failures with OPAT [abstract 293]. In: Program and abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America (IDSA) (San Diego, CA). Alexandria, VA: IDSA, 2003.
150. Crossley K. Long-term care facilities as sources of antibiotic-resistant nosocomial pathogens. Curr Opin Infect Dis 2001; 14:455-9.
151. Tice AD, Barrett T. Home health care. In: Abrutyn E, Goldmann DA, Scheckler WE, eds. Saunders infection control reference service. Philadelphia: W.B. Saunders, 2000; 151-154.
152. Arditi M, Yogev R. Convalescent outpatient therapy for selected children with acute bacterial meningitis. Semin Pediatr Infect Dis 1990; 1:404-10.
153. Bradley JS, Ching DK, Phillips SE. Outpatient therapy of serious pediatric infections with ceftriaxone. Pediatr Infect Dis J 1988; 7: 160-4.
154. Bradley JS, Ching DL, Wilson TA, Compogiannis LS. Once-daily ceftriaxone to complete therapy of uncomplicated group B streptococcal infection in neonates. A preliminary report. Clin Pediatr 1992; 31: 274-8.
155. Dagan R, Phillip M, Watemberg NM, Kassis I. Outpatient treatment of serious community-acquired pediatric infections using once-daily intramuscular ceftriaxone. Pediatr Infect Dis J 1987; 6:1080-4.
156. Goldenberg RI, Poretz DM, Eron LJ, Rising JB, Sparks SB. Intravenous antibiotic therapy in ambulatory pediatric patients. Pediatr Infect Dis 1984; 3:514-7.
157. Gomez M, Maraqa N, Alvarez A, Rathore M. Complications of outpatient parenteral antibiotic therapy in childhood. Pediatr Infect Dis J 2001; 20:541-3.
158. Gutierrez K. Continuation of antibiotic therapy for serious bacterial infections outside of the hospital. Pediatr Ann 1996; 25:639-45.
159. Hooker L, Kohler J. Safety, efficacy, and acceptability of home intravenous therapy administration by parents of pediatric oncology patients. Med Pediatr Oncol 1999; 32:421-6.
160. Leaver JL, Radivan F, Patel L, David TJ. Home intravenous antibiotic therapy: practical aspects in children. J R Soc Med 1997; 90:26-33.
161. Mullen CA, Petropoulos D, Roberts WM, et al. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer. J Pediatr Hematol Oncol 1999; 21:212-8.
162. Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999; 86:126-34.
163. Patrick CC, Shenep JL. Outpatient management of the febrile neutropenic child with cancer. Adv Pediatr Infect Dis 1999; 14:29-47.
164. Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC, Seber A. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol 2000; 34:87-91.
165. Porea TJ, Margolin JF, Chintagumpala MM. Radiological case of the month: pulmonary air embolus with home antibiotic infusion. Arch Pediatr Adolesc Med 2001; 155:963-4.
166. Sudela K. Nursing aspects of pediatric home infusion therapy for the treatment of serious. Semin Pediatr Infect Dis 1990; 1:306-17.
167. Wagner CI, Wagstaff P, Cox TH, Annibale DJ. Early discharge with home antibiotic therapy in the treatment of neonatal infection. J Perinatol 2000; 20:346-50.
168. Wiernikowski JT, Rothney M, Dawson S, Andrew M. Evaluation of a home intravenous antibiotic program in pediatric oncology. Am J Pediatr Hematol Oncol 1991; 13:144-7.
169. Hankins J, Lonsway RAW, Hedrick C, Perdue MD, eds. Infusion therapy in clincial practice. 2d ed. Philadelphia: W.B. Saunders, 2001.
170. Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001; 285:2114-20.
171. Leff B, Burton JR. The future history of home care and physician house calls in the United States. J Gerontol A Biol Sci Med Sci 2001; 56:M603-8.
172. Baumgartner JD, Glauser MP. Single daily dose treatment of severe refractory infections with ceftriaxone: cost savings and possible parenteral outpatient treatment. Arch Intern Med 1983; 143:1868-73.
173. Tice AD, Seibold G, Martinelli LP. OPAT outcomes registry evaluaton of diabetic extremity infections [abstract 291]. In: Program and abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America (IDSA) (San Diego, CA). Alexandria, VA: IDSA, 2003.
174. Dalovisio JR, Juneau J, Baumgarten K, Kateiva J. Financial impact of a home intravenous antibiotic program on a medicare managed care program. Clin Infect Dis 2000; 30:639-42.
175. Eron LJ, Park CH, Hixon DL, Goldenberg RI, Poretz DM. Ceftriaxone therapy of bone and soft tissue infections in hospital and outpatient settings. Antimicrob Agents Chemother 1983; 23:731-7.
176. Eron LJ. Parenteral antibiotic therapy in outpatients: quality assurance and other issues in a protohospital. Chemotherapy 1991; 37(Suppl 2): 14-20.
177. Eron LJ, Passos S. Early discharge of infected patients through appropriate antibiotic use. Arch Intern Med 2001; 161:61-5.
178. Graninger W, Wenisch C, Wiesenger E, Menschik M, Karimi J, Presterl E. Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis. Eur J Clin Microbiol Infect Dis 1995; 14:643-7.
179. Green SL. Practical guidelines for developing an office-based program for outpatient intravenous therapy. Rev Infect Dis 1991; 13(Suppl 2): S189-92.
180. Grizzard MB, Harris G, Karns H. Use of outpatient parenteral antibiotic therapy in a health maintenance organization. Rev Infect Dis 1991; 13(Suppl 2):S174-9.
181. Harris LF, Buckle TF, Coffey FL. Intravenous antibiotics at home. South Med J 1986; 79:193-6.
182. Hindes R, Winkler C, Kane P, Kunkel MJ. Outpatient intravenous antibiotic therapy in Medicare patients: cost-savings analysis. Infect Dis Clin Pract 1995; 4:211-7.
183. Leder K, Turnidge J, Grayson ML. Home-based treatment of cellulitis with twice-daily cefazolin. Med J Aust 1998; 169:519-22.
184. Morales JO, Von Behren L. Secondary bacterial infections in HIV-infected patients: an alternative ambulatory outpatient treatment utilizing intravenous cefotaxime. Am J Med 1994; 97:9-13.
185. Nadworny HA, Markowitz A. Parenteral antibiotic therapy at home: experience with intramuscular cefonicid. Clinical Therapeutics 1987; 10:82-91.
186. Nathwani D, Moitra S, Dunbar J, Crosby G, Peterkin G, Davey P. Skin and soft tissue infections: development of a collaborative management plan between community and hospital care. Int J Clin Pract 1998; 52:456-60.
187. Nathwani D, Morrison J, Seaton RA, France AJ, Davey P, Gray K. Out-patient and home-parenteral antibiotic therapy (OHPAT): evaluation of the impact of one year's experience in Tayside. Health Bulletin 1999; 57:332-7.
188. Nathwani D. The management of skin and soft tissue infections: outpatient parenteral antibiotic therapy in the United Kingdom. Chemotherapy 2001; 47:17-23.
189. Poretz DM. The infusion center: a model for outpatient parenteral antibiotic therapy. Rev Infect Dis 1991; 13(Suppl 2):S142-6.
190. Poretz DM. Treatment of skin and soft-tissue infections utilizing an outpatient parenteral drug delivery device: a multicenter trial. Am J Med 1994; 97:23-7.
191. Rehm SJ, Graham DR, Srinath L, Prokocimer P, Richard MP, Talbot GH. Successful administration of quinupristin/dalfopristin in the outpatient setting. J Antimicrob Chemother 2001; 47:639-45.
192. Smego RJ, Gainer RB. Home intravenous antimicrobial therapy provided by a community hospital and a university hospital. Am J Hosp Pharm 1985; 42:2185-9.
193. Steinmetz D, Berkovits E, Edelstein H, Flatau E, Almany A, Raz R. Home intravenous antibiotic therapy programme, 1999. J Infect 2001; 42:176-80.
194. Stiver HG, Telford GO, Mossey JM, et al. Intravenous antibiotic therapy at home. Ann Intern Med 1978; 89:690-3.
195. Wai AO, Frighetto L, Marra CA, Chan E, Jimenez-Ferreres J. A cost analysis of an outpatient parenteral antibiotic program (OPAT): a Canadian teaching hospital and ministry of health perspective. In: Program and abstracts of the 37th Annual Meeting of the Infectious Diseases Society of America (IDSA) (Philadelphia) [abstract 537]. Alexandria, VA: IDSA, 1999:133.
196. Williams DN, Gibson JA, Bosch D. Home intravenous antibiotic therapy using a programmable infusion pump. Arch Intern Med 1989; 149:1157-60.
197. Eron LJ, Goldenberg RI, Poretz DM. Combined ceftriaxone and surgical therapy for osteomyelitis in hospital and outpatient settings. Am J Surg 1984; 148:1-4.
198. Kunkel MJ, Iannini PB. Cefonicid in a once-daily regimen for treatment of osteomyelitis in an ambulatory setting. Rev Infect Dis 1984; 6:S865-9.
199. Maraqa N, Gomez MM, Rathore MH, Alvarez AM. Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. Clin Infect Dis 2002; 34:50-4.
200. Russo TA, Cook S, Gorbach SL. Intramuscular ceftriaxone in home parenteral therapy. Antimicrob Agents Chemother 1988; 32:1439-40.
201. Tice AD. Osteomyelitis. In: Outpatient parenteral antimicrobial therapy: current status. Scientific American Medicine special report 1997: 55-9.
202. Tice AD. Outpatient parenteral antimicrobial therapy for osteomyelitis. Infect Dis Clin North Am 1998; 12:903-19.
203. Wagner DK, Collier BD, Rytel MW. Long-term intravenous antibiotic therapy in chronic osteomyelitis. Arch Intern Med 1985; 145:1073-8.
204. Wiselka MJ, Nicholson KG. Outpatient parenteral antimicrobial therapy: experience in a large teaching hospital. J Infect 1997; 35:73-6.
205. Rehm SJ, Tomford JW, Longworth DL, Keys TF, McHenry MC. Home intravenous antibiotic therapy (HIVAT) for endocarditis. In: Proceedings of the 30th Annual Meeting of the Infectius Diseases Society of America (IDSA) (Alexandria, VA) [abstract 18]. Alexandria, VA: IDSA, 1992.
206. Esposito S. Treatment of lower respiratory tract infections in Italy: the role of outpatient parenteral antibiotic therapy. Chemotherapy 2001; 47:33-40.
207. Gross R, Graziani AL, Laufer D. Adverse effects of the use of intravenous pentamidine in the home. Infect Dis Clin Pract 1996; 5:456-8.
208. Morales JO, Snead H. Efficacy and safety of intravenous cefotaxime for treating pneumonia in outpatients. Am J Med 1994; 97:28-33.
209. Gilbert J, Robinson T, Littlewood JM. Home intravenous antibiotic treatment in cystic fibrosis. Arch Dis Child 1988; 63:512-7.
210. Hammond LJ, Caldwell S, Campbell PW. Cystic fibrosis, intravenous antibiotics, and home therapy. J Pediatr Health Care 1991; 5:24-30.
211. Kane RE, Jennison K, Wood C, Black PG, Herbst JJ. Cost savings and economic considerations using home intravenous antibiotic therapy for cystic fibrosis patients. Pediatr Pulmonol 1988; 4:84-9.
212. Pond MN, Newport M, Joanes D, Conway SP. Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis. Eur Respir J 1994; 7:1640-4.
213. Trowbridge JF. Outpatient parenteral antibiotic therapy. Management of serious infections. Part II: Amenable infections and models for delivery. Pneumonia and chronic lung disease. Hosp Pract (Off Ed) 1993; 28:16-20.
214. van Aalderen WM, Mannes GP, Bosma ES, Roorda RJ, Heymans HS. Home care in cystic fibrosis patients. Eur Respir J 1995; 8:172-5.
215. Vinks AA, Brimicombe RW, Heijerman HG, Bakker W. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother 1997; 40:125-33.
216. Gross ND, McInnes RJ, Hwang PH. Outpatient intravenous antibiotics for chronic rhinosinusitis. Laryngoscope 2002; 112:1758-61.
217. Esposito S, Noviello S, Ianniello F, D'errico G. Ceftazidime for outpatient parenteral antibiotic therapy (OPAT) of chronic suppurative otitis media due to Psuedomonas aeruginosa. J Chemother 2000; 12: 88-93.
218. Niv A, Nash M, Pieser J. Outpatient management of acute mastoiditis with periosteitis in children. Internat J Pediatr Otorhinolaryng 1998; 46:9-13.
219. Colford JMJ, Corelli RL, Ganz JW, Guglielmo BJ, Jacobs RA. Home antibiotic therapy for streptococcal endocarditis: a call for a controlled trial [letter]. Am J Med 1993; 94:111-2.
220. Francioli PB. Ceftriaxone and outpatient treatment of infective endocarditis. Infect Dis Clin North Am 1993; 7:97-115.
221. Gentry LO, Khoshdel A. New approches to the diagnosis and treatment of infective endocarditis. Texas Heart Institute J 1989; 16:250-7.
222. Huminer D, Bishara J, Pitlik S. Home intravenous antibiotic therapy for patients with infective endocarditis. Eur J Clin Microbiol Infect Dis 1999; 18:330-4.
223. Lopardo G. Management of endocarditis: outpatient parenteral antibiotic treatment in Argentina. Chemotherapy 2001; 47:24-32.
224. Rehm SJ, Weinstein AJ. Endocarditis: medical and surgical management. In: Magilligan D, Quinn E, eds. Home management. New York: Marcel Dekker, 1986:117-27.
225. Stamboulian D. Outpatient treatment of endocarditis in a clinic-based program in Argentina. Eur J Clin Microbiol Infect Dis 1995; 14: 648-54.
226. Miller LK, Wing DA, Paul RH, Grimes DA. Outpatient treatment of pyelonephritis in pregnancy: a randomized controlled trial. Obstet Gynecol 1995; 86:560-4.
227. Bradley JS, Farhat C, Stamboulian D, Branchini OG, Debbag R, Compogiannis LS. Ceftriaxone therapy of bacterial meningitis: cerebrospinal fluid concentrations and bactericidal activity after intramuscular injection in children treated with dexamethasone. Pediatr Infect Dis J 1994; 13:724-8.
228. Plotkin SA. Treatment of bacterial meningitis. Pediatrics 1988; 81: 904-7.
229. Tice AD, Strait K, Ramey R, Hoaglund PA. Outpatient parenteral antimicrobial therapy for central nervous system infections. Clin Infect Dis 1999; 29:1394-9.
230. Johansson E, Bjorkholm M, Wredling R, Kalin M, Engervall P. Outpatient parenteral antibiotic therapy in patients with haematological malignancies: a pilot study of an early discharge strategy. Support Care Cancer 2001; 9:619-24.
231. Kaplinsky C, Drucker M, Goshen J, Tamary H, Cohen IJ, Zaizov R. Ambulatory treatment with ceftriaxone in febrile neutropenic children. Isr J Med Sci 1994; 30:649-51.
232. Mustafa MM, Aquino VM, Pappo A, Tkaczewski I, Buchanan GR. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. J Pediatr 1996; 128:847-9.
233. Sahu S, Bapna A, Pai SK, Nair CN, Kurkure PA, Advani SH. Outpatient antimicrobial protocol for febrile neutropenia: a nonrandomized prospective trial using ceftriaxone, amikacin, and oral adjuvant agents. Pediatr Hematol Oncol 1997; 14:205-11.
234. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994; 12:107-14.
235. Tice AD. Outpatient parenteral antibiotic therapy for fever and neutropenia. Infect Dis Clin North Am 1998; 12:963-77.
236. Heley A. Foscarnet infusion at home. Lancet 1988; 2:1311.
237. Wood G, Whitby M, Hogan P, Frazer I. Foscarnet infusion at home. Lancet 1989; 1:156.